STAT+: FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
STAT
DECEMBER 19, 2024
The Food and Drug Administration on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper copies of the injection. The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.
Let's personalize your content